NEW YORK, May 28 /PRNewswire/ -- Following the feature of the UltraPulse CO2 fractional laser as a Miracle Treatment for Burn Scars on The Today Show, The Insider will also be featuring the treatment tonight, check your local listings for the time.
Chandra, Jordan and Trae Berns were interviewed today by The Insider. The interview focused on how and when they got their burns they have lived with for 20 years. The girls also discussed their journey through the treatment process with Dr. Jill Waibel, the treating physician. Specifically, they discussed how the Lumenis UltraPulse Laser has helped to minimize both the unwanted color and roughness of their scars. Lastly, they expressed their happiness in the results of the treatments thus far and look forward to additional treatments and results in the next 3 months.
Dr. Jill Waibel was also interviewed for the segment, in which she discussed the fractional treatment she performed on the girls using the Lumenis laser. Specifically, Dr. Waibel talked about the TotalFX, ActiveFX and DeepFX treatments that were used on the girl's burn scars.
Lumenis pioneered skin resurfacing over 18 years ago with its C02 lasers. The Lumenis UltraPulse laser system has FDA clearance for more than 34 indications and is referenced in excess of 90 peer-reviewed publications. Although frequently used for aesthetic applications, the UltraPulse offers 240 watts of power and microsecond pulses which combined provide a broad canvas from which other treatments in cutaneous surgical and aesthetic applications can be provided.
The entire story of the Berns triplets and their treatments using the UltraPulse Fractional CO2 laser can be found at www.bernstriplets.com.
Lumenis Ltd,. a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, is Israel's largest medical device company with more than 800 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over 100 countries, and an installed base of over 70,000 systems. For more information about Lumenis and its products, log onto www.lumenis.com.
Contacts: Charly Rok Michelle Maydan Lippe Taylor Director of Corporate Communications Office: 212-598-4400 x155 Lumenis Cell: 917-912-2863 Toll-free: 1-866-569-0597 firstname.lastname@example.org Office: +972-4-959-9004 email@example.com
Lumenis(R) is a registered trademark of Lumenis Ltd.
UltraPulse(R) is a trademark of Lumenis Ltd.
Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled "Risk Factors", as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.
|SOURCE Lumenis Ltd.|
Copyright©2009 PR Newswire.
All rights reserved